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1078–5Aim. To assess the safety and efficacy of sclerotherapy of the great saphenous vein (GSV) comparing standardised polido-
canol foam to liquid polidocanol in a randomised controlled trial (RCT).
Methods. A multicentre randomised controlled clinical trial was carried out in which saphenous trunks were treated by
sclerotherapy. 106 patients with primary varicose veins due to an incompetent GSV were treated with either standardised
3% polidocanol foam or 3% liquid polidocanol. The primary efficacy criterion was elimination of reflux (<0.5 sec) mea-
sured 3 cm below the sapheno-femoral junction (SFJ) by duplex ultrasonography 3 months after the last injection.
Results. A significantly greater number of patients were successfully treated by foam sclerotherapy resulting in 69% elim-
ination of reflux compared to 27% patients treated with liquid sclerosant. The secondary endpoints of vein occlusion, reflux
time, refilling time and patient satisfaction also improved significantly more in the foam group. The mean number of treat-
ment sessions was 1.3 in the foam group compared to 1.6 in the liquid group. Differences between study centres occurred
with a mean of 96% reflux elimination in 6 centres versus 39% in 4 other centres. Centres with a high response rate in-
jected a higher mean volume (4.3 vs. 3.6 ml) in the first session in a vein with a smaller diameter (7.5 mm vs. 8.4 mm). No
difference in adverse drug reactions was observed between treatment groups.
Conclusions. Standardised 3% polidocanol foam is more efficient and equally safe compared to 3% liquid polidocanol for
treatment of GSV. In comparison to other studies a relatively small volume was injected into relatively large veins.
 2007 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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For many years surgical treatment has been the main
method of treating patients with venous disease in
the lower limb attributable to saphenous truncal in-
competence. Endovenous radiofrequency1e5 or laser
ablation6e8were established as alternativeswith prom-
ising results. Widespread use of these methods has
been limited in many countries due to the cost of pro-
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884/000238+ 08 $34.00/0  2007 European Society for Vasculasclerotherapy is inexpensive, easy to use in experi-
enced hands, requires only a minimum of equipment.
The treatment may be repeated several times to im-
prove the outcome of treatment. Since the introduction
of duplex-guided injection,9e11 sclerotherapy has expe-
rienced a renaissance for the treatment of larger vari-
cose veins, especially when used to deliver foamed
sclerosing agents.
A number of clinical series using foam sclerother-
apy of the GSV has been published in recent years
by several authors from all over the world who
have used the sclerosants sodium tetradecyl sul-
phate,12e14 polidocanol15e17 or both.18e20 Relatively
few controlled clinical trials have been reported in
comparison21e25 substantiating the use of foam sclero-
therapy for the treatment of the GSV. The aim of this
publication is to present the results of the first phase
of a GCP-compliant multicentre trial performed to in-
vestigate the safety and efficacy of polidocanol foam.
Long-term results after 12 months of patients thatr Surgery. Published by Elsevier Ltd. All rights reserved.
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a future publication.
Materials and Methods
A Good Clinical Practice (GCP) compliant, prospec-
tive, randomised, comparative multicentre study
was designed to evaluate efficacy and safety of stand-
ardised 3% polidocanol foam for treatment of patients
with incompetence of the great saphenous vein (GSV)
in comparison to liquid sclerotherapy with 3% polido-
canol. The study (ESAF) was conducted between De-
cember 2004 and March 2007 (first study phase ended
June 2006). The approval of the German Health Au-
thority (BfArM) was received and the protocol for
the study considered and approved by the Ethics
Committee of the University of Bonn. The detailed
study protocol included: explicit description of study
procedures, statistical analysis plan, 100% monitoring
of study data, double data entry, several independent
study audits and inspections, evaluation of ultra-
sound images by an outcome quality committee,
and assessment of correct ultrasound settings in
each centre by the principal investigator. The study
was funded by Chemische Fabrik Kreussler & Co.
GmbH, Wiesbaden, Germany according to GCP rules.
Study centres: All study centres had considerable
experience in treating patients using liquid sclerother-
apy. Before the start of the study all investigators
where trained in the use of the device used to manu-
facture foam.
Patients: Patients were included with the following
inclusion criteria: incompetent GSV with a diameter
less than 12 mm measured in upright position 3 cm
below the sapheno-femoral junction (SFJ), incompe-
tent terminal valve, reflux duration of 1 second or
more measured 3 cm below the SFJ under Valsalva
manoeuvre, and refilling time measured by photople-
thysmography (PPG) of less than 25 sec. OtherTable 1. Demographic data of liquid- and foam-treated patients (ful
Polidocanol liquid
Age (year) 49.8 (19 e 69)
Gender female
39
Weight (kg) 75.3 (52 e 132)
Height (cm) 170 (153 e 194)
Body mass index (kg/m2) 25.9 (18.0 e 34.1)
Diameter at 3 cm (mm) 7.7 (3.7 e 11.8)
Reflux time at 3 cm (sec) 3.4 (1.0 e 7.9)
Reflux time at 25 cm (sec) 3.4 (0.0 e 7.2)
CEAP C2
C3
C4
C5inclusion criteria were: reflux in the GSV from the
SFJ at least to the knee, CEAP-classifications: C2 e
C5, EP, As, PR, age between 18 and 70 years. Patients
with a history of deep vein thrombosis, superficial
thrombosis, major leg oedema, known patent foramen
ovale, and known predisposition to migraine were ex-
cluded from the trial. Only patients who gave their in-
formed written consent were included in the clinical
trial.
Eleven study centres in Germany, including both
private practices and hospitals, treated 108 patients.
The full analysis set and the per-protocol set (PP-set)
consisted of 106 respectively 92 patients. No relevant
differences concerning age, height, weight, gender, di-
ameter of GSV and reflux at 3 cm and 25 cm below the
SFJ, and CEAP-classification were present between
both study groups (Table 1).
Study medication: Standardised polidocanol foam
was prepared by using the EASY-FOAM kit (two
10 mL silicone-reduced syringes, connected by
a two-way valve connector, with one syringe pre-
filled with 7.4 mL sterile air (Laboratoire Kreussler
Pharma, Paris, France)). After aspiration of 1.6 mL po-
lidocanol 3% (Aethoxysklerol 3%, Chemische Fabrik
Kreussler & Co. GmbH, Wiesbaden, Germany) into
the other syringe (1:5.6) standardised movements of
the syringe plungers were achieved by using the Tur-
bofoam machine,22 with a controlled number of
movements, speed, and power. In the liquid group
Aethoxysklerol 3% was used. The maximum doses
per treatment session were limited to 5 mL polidoca-
nol foam and 4 mL liquid. For reasons of safety
a foam volume has been chosen that is lower than
the volume of 6e8 mL which has been estimated as
safe during the 1st European Consensus Conference
on Foam Sclerotherapy.26
Venous examination: Venous duplex assessment
was performed according to a standard protocol
with the patient in the standing position with thel analysis set). All data are represented by the mean and range
Polidocanol foam
50.5 (25 e 68)
male female male
13 35 19
79.7 (54 e 110)
173 (156 e 210)
26.7 (18.3 e 39.5)
7.5 (1.0 e 10.9)
3.7 (1.3 e 7.9)
3.3 (1.3 e 7.4)
26 26
14 15
8 12
4 1
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240 E. Rabe et al.weight taken on the contralateral limb. Reflux was as-
sessed after a Valsalva manoeuvre supervised by the
physician. Print-outs showing reflux time were evalu-
ated at the end of study by an independent outcome
quality committee. The diameter of the GSV was mea-
sured with the patient in the standing position in the
cross sectional view. Occlusion of the treated vein was
evaluated by applying pressure to the vein in trans-
verse view via the transducer. An incompressible
vein was considered to be obliterated. Images of the
assessments were recorded for review by the outcome
quality committee. PPG was performed with the
patient sitting in a relaxed position, legs slightly ex-
tended, and dorsiflexions were repeated 8 times
within 15 sec. Normal refilling-time was defined as
being more than 25 sec.28
Treatment: During treatment patients lay supine to
minimise the risk of syncope. An 18 g venipuncture
catheter was inserted into the GSV under ultrasound
guidance. Venous canulation was invariably in the
thigh at the safest and most easily accessible site
and at least 10 cm below the SFJ. Injection was given
slowly whilst the patient lay in the recumbent posi-
tion. Only one injection per session was allowed in
order to standardise treatment. Further treatment ses-
sions were arranged 2 weeks and 4 weeks following
the first. The presence of venous reflux was assessed
3 cm below the SFJ and if this was still above 0.5 sec
further sclerotherapy was performed. Following treat-
ment patients lay supine for 5 minutes. A German
class 2 (30 mm Hg) thigh length stocking was then ap-
plied. Patients were asked to wear this for at least 8
hours a day for a 14 day period. Patients were advised
to continue their normal daily activities, whilst avoid-
ing strenuous sports, extreme physical activities, sun
bathing and saunas.
Efficacy and safety: Patients were re-assessed 3
months following completion of the final sclerother-
apy session. Duplex ultrasonography and photople-
thysmography were repeated in accordance with the
protocol. The primary efficacy criterion was elimina-
tion of venous reflux of duration >0.5 sec at a location
3 cm distal to the SFJ 3 months following completion
of treatment. Secondary efficacy criteria included oc-
clusion of the GSV 3 cm and 25 cm distal to the SFJ
as judged by duplex ultrasonography. Patients com-
pleted the CIVIQ questionnaire prior to commencing
the study and 3 months after last injection in order
to record baseline quality of life and possible im-
provements. The Chronic Venous Insufficiency Ques-
tionnaire (CIVIQ) consisting of 19 questions and 5
possible answers per question (i.e. ‘‘not affected’’ (1),
‘‘somewhat affected’’ (2), ‘‘moderately affected’’ (3),
‘‘highly affected’’ (4), and ‘‘impossible’’ (5) is a verifiedEur J Vasc Endovasc Surg Vol 35, February 2008tool for measuring quality of life in patients with ve-
nous disease in the lower limb. Patients also reported
their assessment of the outcome of treatment to the
managing specialist. The patients’ assessment was re-
corded on a 5 point scale as: ‘‘deteriorated’’, ‘‘no
change’’, ‘‘improved slightly00, ‘‘improved nicely’’ or
‘‘improved excellent’’. Clinical examination was per-
formed to obtain an assessment of the clinical out-
come. During the treatment and the follow-up
period any adverse events and adverse drug reactions
were recorded.
Statistics: We based our sample size on the data
published by Yamaki.25 Assuming an efficacy of 20%
for the liquid and 60% for foam treatment, a study
with a 90% power to find a difference at the 5% level
would require 48 patients per group, which we in-
creased to 60 to allow for withdrawals. The primary
hypothesis was tested using the common binominal
test for the difference in rates based on the normal
approximation. In addition the primary efficacy pa-
rameter elimination of reflux 3 cm below SFJ was an-
alysed using a logistic regression model. Binary or
ordinal scaled secondary efficacy variables, including
the occlusion of GSV (yes/no), the number of treat-
ments (1, 2, or 3) and the patient’s and physician’s sat-
isfaction (1 through 5) were analyzed by a logistic
regression model, whereas for continuous secondary
efficacy variables, including refilling phase and CIVIQ
an analysis of covariance (ANCOVA) was used.Results
Patients: The total study population comprised 108
patients with an incompetent GSV. 106 patients, con-
sisting of 74 women (70%) and 32 men (30%), were el-
igible for the full analysis set, 92 patients, consisting of
63 women (68%) and 29 men (32%) were eligible for
the per protocol set (PP-set) (Fig. 1).
Efficacy: Patients in whom venous reflux 3 cm be-
low the SFJ had been eliminated on duplex ultraso-
nography 3 months after completion of treatment
were regarded as ‘‘responders’’. The total response
rate was 69% in the full analysis set and 70% in the
PP-set for foam treated patients. However this rate
was significantly ( p< 0.0001) lower in the group of
patients treated with liquid sclerosant with 27%
responders in the full analysis set and 31% in the
PP-set. The mean reflux time in the GSV (full analysis
set) at 3 cm decreased from 3.4 sec to 1.1 sec for foam
and from 3.7 sec to 2.3 sec for liquid treated patients.
Reflux at 25 cm also decreased in foam treated pa-
tients (3.3 sec to 0.9 sec). In the liquid sclerosant
treated patients this was less pronounced (3.2 sec to
Patients enrolled:
n = 122
Patients randomised:
n = 108
Screening Failures:
n = 14
Patients treated:
n = 108
Patients not treated:
n = 0 
Completed:
n = 54 
Completed:
n = 52 
Reasons for Withdrawal:
Violation to entry criteria n = 1 
Withdrawn:
n = 1
Withdrawn:
n = 1 
Reasons for Withdrawal 
Violation to entry criteria n = 1
KRS-Poli-3    Liquid:
n = 53
KRS-Poli-3    Foam:
n = 55   
Fig. 1. CONSORT diagram showing flow of patients through the study.
Table 2. Number of treatment sessions (full analysis set)
Polidocanol liquid Polidocanol foam
Responder
(n¼ 13)
Non-
responder
(n¼ 36)
Responder
(n¼ 37)
Non-
responder
(n¼ 15)
one session 7 13 28 8
two sessions 4 4 6 2
three sessions 2 19 3 5
mean number
of treatment
sessions
1.6 2.2 1.3 1.8
241Efficacy and Safety of Great Saphenous Vein Sclerotherapy2.2 sec). The number of patients with an occluded
GSV was significantly greater following foam treat-
ment 3 cm (foam¼ 29 patients (54%); liquid¼ 9 pa-
tients (17%), p¼ 0.0001) and 25 cm below the SFJ
(foam¼ 33 patients; liquid¼ 12 patients, p< 0.0001).
The mean PPG refilling time increased from 13.6 sec
to 27.4 sec for foam treated patients compared to
12.6 sec to 19.5 sec for liquid sclerosant treated pa-
tients ( p¼ 0.0017). The GSV diameter measured at
3 cm and 25 cm below SFJ decreased in both treatment
groups, but foam treated patients (7.7 mm to 5.8 mm
at 3 cm or 6.5 mm down to 5.5 mm at 25 cm) showed
a greater difference than patients treated by liquid
sclerotherapy (7.4 mm to 6.2 mm at 3 cm and 6.3 mm
down to 5.5 mm at 25 cm).The results obtained from the CIVIQ question-
naires showed that before treatment the mean
values for foam sclerosant treated patients were 32
and 34 for liquid. These values improved to 25 afterEur J Vasc Endovasc Surg Vol 35, February 2008
Table 3. ‘‘Responders’’ in the different study centres (PP-set)
Centre No. Polidocanol liquid Centre No. Polidocanol foam
a (n¼ 8) 3 (38%) a (n¼ 9) 9 (100%)
b (n¼ 6) 1 (17%) b (n¼ 7) 3 (43%)
c (n¼ 5) 0 (0%) c (n¼ 4) 1 (25%)
d (n¼ 3) 2 (67%) d (n¼ 3) 3 (100%)
e (n¼ 5) 2 (40%) e (n¼ 7) 6 (86%)
f (n¼ 3) 2 (67%) f (n¼ 4) 4 (100%)
g (n¼ 0) — g (n¼ 2) 2 (100%)
h (n¼ 7) 1 (14%) h (n¼ 8) 5 (63%)
j (n¼ 3) 0 (0%) j (n¼ 4) 0 (0%)
k (n¼ 1) 0 (0%) k (n¼ 0) —
l (n¼ 2) 2 (100%) l (n¼ 2) 2 (100%)
242 E. Rabe et al.foam treatment and to 30 after liquid sclerosant
treatment.
The patients self-reported assessment of the out-
come showed that only 15 patients treated with
foam assessed their treatment satisfaction as ‘‘deterio-
rated’’, ‘‘no change’’, or ‘‘improved slightly00, whereas
36 patients voted for ‘‘improved nicely’’ or ‘‘improved
excellent’’. Among the liquid treated patients only 22
voted for ‘‘improved nicely’’ or ‘‘improved excellent’’.
The patient satisfaction was significantly ( p¼ 0.0008)
higher in the foam group than in the liquid group.
The physician’s assessment showed similar results.
For 36 patients treated with foam the investigators
gave a favourable opinion, this being significantly
( p< 0.0001) better than the 15 liquid-treated patients.
The number of treatment sessions needed for com-
plete success was significantly ( p¼ 0.0016) lower in
the foam-treated group (1.3) in comparison to liquid
(1.6) (Table 2). The mean injection volume in all ses-
sions was 3.8 mL in the foam group and 3.3 mL in
the liquid group.
The response rate differed greatly between study
centres, as shown in Table 3. Five of the study centres
who treated patients with polidocanol foam reached
a response rate of 100%. Another centre only had 1
non-responder out of 7 patients (86%). Yet anotherTable 4. Vein and injection parameters in the different study centre
Centre No. Age kg 1st injection:
mL
1st injection:
at cm below SFJ
a (n¼ 9) 57 86 4.4 17.8
d (n¼ 3) 42 89 4.8 15.8
e (n¼ 7) 52 76 4.6 18.4
f (n¼ 4) 55 71 4.3 19.8
g (n¼ 2) 37 64 2.9 22.7
l (n¼ 2) 58 80 4.0 20.5P
52 79 4.3 18.6
b (n¼ 7) 56 84 3.9 18.4
c (n¼ 4) 52 86 2.9 21.6
h (n¼ 8) 48 85 4.3 14.4
j (n¼ 4) 34 70 2.3 10.0P
49 82 3.6 16.1
Eur J Vasc Endovasc Surg Vol 35, February 2008centre had 5 responders among 8 patients (63%). In
contrast 3 study centres reached only a rate below
50%. Therefore 6 study centres reached a response
rate for foam of 96% in comparison to the remaining
4 centres with a rate of 39%. The main patient and in-
jection parameters are listed in Table 4.
A comparison between ‘‘responders’’ of all centres
and ‘‘non-responders’’, revealed a statistically signifi-
cant difference between the covariates diameters of
GSV at 3 cm ( p¼ 0.042) and amounts of sclerosant
( p¼ 0.024). All other characteristics were the same.
Adverse events: Adverse events were continuously
recorded during the whole study. Adverse drug reac-
tions (ADRs) were observed in 39 patients, with 17 pa-
tients of them belonging to the foam group and 22 to
the liquid group (Table 5). No serious ADR resulting
in a life threatening complication or one necessitating
hospitalisation was observed.Discussion
The results of this randomised controlled trial show
a significantly higher response rate for standardised
3% polidocanol foam compared to 3% liquid polidoca-
nol for treatment of the incompetent great saphenous
vein (GSV). Liquid sclerosant eliminated venous reflux
in 30% of patients after a maximum of 3 treatment
sessions.
It was infeasible to perform this study using a ‘dou-
ble-blind’ protocol. The investigator would rapidly
learn the identity of the sclerosant since foamed scle-
rosants are strongly echogenic on ultrasound imaging
and their injection is readily identified. In order to re-
veal any bias of the investigator in assessing the out-
come the ultrasound evaluations of each investigator
were double-checked by an outcome quality commit-
tee who examined the printed ultrasound images of
examinations. No discrepancies were detected ands
Visit 1: GSV
diameter (cm)
Visit 1: Reflux (sec)
at 3 cm below SFJ
Elevation of leg
after injection
7.5 3.2 no
8.4 3.0 yes, 45
7.4 5.1 no
6.9 1.9 yes
8.6 5.3 yes, 70
7.1 4.6 yes, 20
7.5 3.7
8.7 4.6 yes, 45
8.5 4.3 yes, 40
8.0 1.9 yes, 30
8.3 5.4 yes, 30e40
8.4 3.7
Table 5. Adverse drug reactions (ADR), first study phase (108
patients)
ADRs as reported by investigators Polidocanol
liquid
Polidocanol
foam
Pain 6 7
Haematoma 7 3
Phlebitis or thrombophlebitis or
sense of pressure along
treated
vein or red flash along the
vein
6 7
Induration or mild tension 3 4
Pigmentation or
hyperpigmentation
4 5
Itching or urticaria 2 1
Dysthesia or paraesthesia 1 3
Metallic taste or paraesthesia
tongue
3 __
Hypertension __ 2
Matting 1 __
Seborrhoic eczema __ 1
243Efficacy and Safety of Great Saphenous Vein Sclerotherapyin only one case was an image declared ‘‘not evalu-
able’’ by the members of the committee. A response
rate (elimination of reflux) of polidocanol foam for
the treatment of incompetent GSV of 69% three
months after the last injection and a rate of 54%
occluded GSVs are high success rates taking into
account the mean diameter of the GSV which was
7.9 mm. Incompetent saphenous tributaries were not
treated during this study phase, and only 1.3Table 6. Injected foam volume, efficacy criteria and rates in other R
Injected volume
of foam
Number of
foam patients
Monocentre
randomised
controlled trial21
5.3 mL 1% polidocanol
foam (1:5)
40
5.1 mL 3% polidocanol
foam (1:5)
40
Multicentre
randomised
controlled
multicentre trial22
3.3 mL 1% or 3%
polidocanol foam (1:5)
158
144
Mono(two?)centre
randomised
controlled
multicentre trial23
2.0e2.5 mL 3%
polidocanol
foam (1:5)
45
Multicentre
randomised
controlled
multicentre trial24
14.9 mL e 24.9 mL 1%
polidocanol
foam (Varisolve)
428
416
Monocentre
randomised
controlled trial25
2 mL 1% polidocanol
foam (1:6) for each
tributary vein draining
into the GSV plus 1 mL 3%
polidocanol
foam injected into GSV
37
(ESAF-study)
multicentre
randomised
controlled trial
3.8 mL polidocanol
foam (1:5.6)
54treatment sessions with one injection per session
were done with an average of 3.8 mL foam. Some of
the published RCTs were single centre, in some trials
significantly higher foam volumes were used, some-
times smaller GSVs were treated or tributaries were
injected during the same session (Table 6). In compar-
ison with other work we may have used a suboptimal
treatment approach. This study was conducted for
submission to regulatory authorities; therefore patient
safety, standardisation, strict methodology, and legal
value of our study were important factors. Our data
were collected in such a way that a direct comparison
could be made of the relative efficacy of foam and liq-
uid sclerosants. In clinical practice it would be usual
to address saphenous varices, tributaries and acces-
sory veins in the same course of treatment. This
may explain why data from clinical series appears to
show results superior to those described in this paper.
Substantial differences were present between cen-
tres in this study since 6 study centres reached a ‘‘re-
sponse’’ rate of 96% in comparison to the remaining
4 centres with a rate of 39%. Centres with a high re-
sponder rate injected a mean of 4.3 mLwith a mean di-
ameter of the GSV at inclusion of 7.5 mm. In contrast
centres with a lower responder rate injected 3.6 mL
foam inGSVswith ameandiameter of 8.4 mm.Accord-
ing to the study protocol the maximum foam volumeCTs
Diameter of
GSV before
treatment
Efficacy criteria Efficacy rate
5.4 mm 1 year
after treatment: complete
occlusion of the treated
veins
69.5%
6.4 mm 82.1%
6.1 mm 3 weeks
after treatment:
disappearance
of a pathological reflux
91%
6 months
after treatment
80%
4e8 mm 3 weeks
after one treatment
session: elimination
of reflux
84%
7.1 mm after 3 months:
occlusion of incompetent
trunk and elimination
of reflux (<0.5sec)
83.4%
after 12 months 78.9%
no information after 12 months:
complete occulusion
of GSV
67.6%
7.9 mm 3 months
after last injection:
elimination of reflux
(<0.5 sec) 3 cm below SFJ
69%
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244 E. Rabe et al.was restricted to 5 ml. In addition only one injection per
session was allowed in this trial to increase standard-
isation. During the 1st European Consensus Confer-
ence on Foam Sclerotherapy26 a maximum volume of
6e8 mL per session was considered to be safe, in the
meantime it was increased to 10 mL per session by
the 2nd European Consensus Conference 2006.27 With
the excellent safety results of this study on hand the
maximum foam volume per session can be increased
in future trials. In daily practicemore than one injection
along the GSV and in tributaries may be performed.25
The safety data from this study clearly demonstrate
that foam sclerotherapy is as safe as liquid sclerother-
apy if a restricted foam volume is used. No serious
adverse drug reactions were observed. In contrast to
one RCT,24 where considerably higher amounts of
foam were used, neither a deep vein thrombosis, nor
pulmonary embolism was observed in our trial. Side
effects that were observed in this study belonged to
those already known for liquid sclerotherapy. These
data coincide with data published in 2005 showing
the results of an extensive review of patients also
treated by foam and liquid.29
These study results, collected according to the proto-
col 3 months after last injection, are the first results of
the ESAF-study. In the second part of this trial aiming
at long term results after one year only responders
will be included. After possible injection of tributaries
with 1% polidocanol foam (1:5.6) all efficacy and safety
parameters will be analyzed and discussed 12 months
after last GSV injection in a further publication.Acknowledgements
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